We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

Fund managers haven’t disclosed any holdings of VTGN yet.

VTGN Hedge Fund Activity: Q1 2026 in Review

56 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2026, worth a combined $8.12M — down 8.1% from $8.84M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new VTGN positions and 14 closed out — a net gain of 2 holders — while 14 added to existing stakes and 9 trimmed.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $358K. The largest seller was Jane Street, cutting an estimated $155K.

  • 56 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2026, up from 55 in Q4 2025.
  • Funds reported $8.12M of VistaGen Therapeutics stock for Q1 2026, down 8.1% quarter-over-quarter.
  • 16 funds opened new VistaGen Therapeutics positions in Q1 2026 and 14 closed out, a net change of +2 holders.
  • The largest VistaGen Therapeutics buyer in Q1 2026 was Acadian Asset Management, an estimated $358K added.
  • The largest VistaGen Therapeutics seller in Q1 2026 was Jane Street, an estimated $155K sold.

Based on aggregated 13F filings for Q1 2026.